We develop innovative therapeutics to protect and improve the vision of patients with a range of retinal diseases and conditions.
Learn More

ONL Therapeutics is a clinical-stage biopharmaceutical company committed to helping patients see the future.

Clinical Trials

The company’s lead therapeutic candidate, ONL1204, is a first-in-class small peptide that is being studied in multiple diseases.

Science

Our primary scientific focus is Fas-mediated signaling, initiated by the activation of the Fas receptor at the cell surface and implicated in a variety of diseases.

Category: News

  • ONL Therapeutics Wins Emerging Company Showcase at MichBio Expo

    ONL Therapeutics Wins Emerging Company Showcase at MichBio Expo Crain’s Detroit – 10/02/14by Tom HendersonONL Therapeutics was named the first place winner in the Emerging Company Showcase at the MichBio Expo winning a $2,500 first prize.  See article in Crain’s Detroit below: Read the Article

  • ONL ANNOUNCES LEADERSHIP CHANGES

    ONL ANNOUNCES LEADERSHIP CHANGES ONL ANNOUNCES LEADERSHIP CHANGESOctober 29, 2013 Ann Arbor, Mich. (October 29, 2013) — ONL Therapeutics today announced the appointments of John Freshley as Chief Executive Officer and Anna Schwendeman as Vice President of Preclinical Development. These appointments follow the sad loss of Co-Founder and former CEO Raili Kerppola to adrenal cancer…

  • ONL RECEIVES ORPHAN DRUG DESIGNATION FOR ONL-101 IN RETINAL DETACHMENT

    ONL RECEIVES ORPHAN DRUG DESIGNATION FOR ONL-101 IN RETINAL DETACHMENT ONL RECEIVES ORPHAN DRUG DESIGNATION FOR ONL-101 IN RETINAL DETACHMENTMarch 19, 2013 Ann Arbor, Mich. (March 19, 2013) — ONL Therapeutics today announced that it has received an orphan drug designation form the FDA for ONL-101 in its lead indication of retinal detachment. Orphan drug…